{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:38:13Z","timestamp":1793608693160,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"publisher","award":["P50AR070604"],"award-info":[{"award-number":["P50AR070604"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.omtn.2022.10.025","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T20:11:22Z","timestamp":1668024682000},"page":"479-492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Systemic PPMO-mediated dystrophin expression in the Dup2 mouse model of Duchenne muscular dystrophy"],"prefix":"10.1016","volume":"30","author":[{"given":"Liubov V.","family":"Gushchina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana A.","family":"Vetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma C.","family":"Frair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6148-457X","authenticated-orcid":false,"given":"Adrienne J.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6668-4818","authenticated-orcid":false,"given":"Kelly M.","family":"Grounds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob W.","family":"Lay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nianyuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1090-6773","authenticated-orcid":false,"given":"Aisha","family":"Suhaiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick J.","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabatha R.","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5892-3639","authenticated-orcid":false,"given":"Nicolas","family":"Wein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Flanigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2022.10.025_bib1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","article-title":"Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis","volume":"15","author":"Crisafulli","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtn.2022.10.025_bib2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ajmg.a.30617","article-title":"Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort","volume":"134","author":"Dent","year":"2005","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.omtn.2022.10.025_bib3","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1002\/humu.21114","article-title":"Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort","volume":"30","author":"Flanigan","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2022.10.025_bib4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/mus.20586","article-title":"Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule","volume":"34","author":"Aartsma-Rus","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtn.2022.10.025_bib5","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/humu.20367","article-title":"Duplications in the DMD gene","volume":"27","author":"White","year":"2006","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2022.10.025_bib6","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/14712598.2017.1271872","article-title":"Exon skipping: a first in class strategy for Duchenne muscular dystrophy","volume":"17","author":"Niks","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.omtn.2022.10.025_bib7","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1038\/mtna.2014.8","article-title":"Targeted exon skipping to correct exon duplications in the dystrophin gene","volume":"3","author":"Greer","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2022.10.025_bib8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3233\/JND-170233","article-title":"Efficient skipping of single exon duplications in DMD patient-derived cell lines using an antisense oligonucleotide approach","volume":"4","author":"Wein","year":"2017","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.omtn.2022.10.025_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-1-4939-8651-4_2","article-title":"An overview of recent advances and clinical applications of exon skipping and splice modulation for muscular dystrophy and various genetic diseases","volume":"1828","author":"Rodrigues","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omtn.2022.10.025_bib10","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: first approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.omtn.2022.10.025_bib11","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2022.10.025_bib12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3233\/JND-170272","article-title":"Long-term pulmonary function in Duchenne muscular dystrophy: comparison of eteplirsen-treated patients to natural history","volume":"5","author":"Kinane","year":"2018","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.omtn.2022.10.025_bib13","doi-asserted-by":"crossref","first-page":"e2146","DOI":"10.1212\/WNL.0000000000005680","article-title":"Eteplirsen treatment for Duchenne muscular dystrophy: exon skipping and dystrophin production","volume":"90","author":"Charleston","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2022.10.025_bib14","doi-asserted-by":"crossref","first-page":"e15858","DOI":"10.1097\/MD.0000000000015858","article-title":"Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy","volume":"98","author":"Alfano","year":"2019","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.omtn.2022.10.025_bib15","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1358\/dot.2020.56.8.3159186","article-title":"Golodirsen for Duchenne muscular dystrophy","volume":"56","author":"Anwar","year":"2020","journal-title":"Drugs Today"},{"key":"10.1016\/j.omtn.2022.10.025_bib16","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.omtn.2022.10.025_bib17","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","article-title":"Viltolarsen: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.omtn.2022.10.025_bib18","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/mt.2010.151","article-title":"Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO","volume":"18","author":"Yin","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2022.10.025_bib19","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1093\/hmg\/ddn293","article-title":"Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function","volume":"17","author":"Yin","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2022.10.025_bib20","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.omtm.2020.03.011","article-title":"Combined treatment with peptide-conjugated phosphorodiamidate morpholino oligomer-PPMO and AAV-U7 rescues the severe DMD phenotype in mice","volume":"17","author":"Forand","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2022.10.025_bib21","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s11095-021-03118-5","article-title":"Pharmacokinetic\/pharmacodynamic modeling of a cell-penetrating peptide phosphorodiamidate morpholino oligomer in mdx mice","volume":"38","author":"Mukashyaka","year":"2021","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.omtn.2022.10.025_bib22","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/17425255.2021.1992382","article-title":"Antisense oligonucleotides: absorption, distribution, metabolism, and excretion","volume":"17","author":"Shadid","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.omtn.2022.10.025_bib23","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.omtn.2019.09.012","article-title":"Hexose potentiates peptide-conjugated morpholino oligomer efficacy in cardiac muscles of dystrophic mice in an age-dependent manner","volume":"18","author":"Han","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2022.10.025_bib24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/978-1-4939-8651-4_23","article-title":"In\u00a0vivo evaluation of multiple exon skipping with peptide-PMOs in cardiac and skeletal muscles in dystrophic dogs","volume":"1828","author":"Maruyama","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omtn.2022.10.025_bib25","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/nm.3628","article-title":"Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice","volume":"20","author":"Wein","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2022.10.025_bib26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.omtm.2021.03.014","article-title":"Pre-clinical dose-escalation studies establish a therapeutic range for U7snRNA-mediated DMD exon 2 skipping","volume":"21","author":"Simmons","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2022.10.025_bib27","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.nmd.2015.08.005","article-title":"The first exon duplication mouse model of Duchenne muscular dystrophy: a tool for therapeutic development","volume":"25","author":"Vulin","year":"2015","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2022.10.025_bib28","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1089\/hum.2020.286","article-title":"Lack of toxicity in non-human primates receiving clinically relevant doses of an AAV9.U7snRNA vector designed to induce DMD exon 2 skipping","volume":"32","author":"Gushchina","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2022.10.025_bib29","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2022.10.025_bib30","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.nmd.2009.08.010","article-title":"DMD Trp3X nonsense mutation associated with a founder effect in North American families with mild Becker muscular dystrophy","volume":"19","author":"Flanigan","year":"2009","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2022.10.025_bib31","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/humu.20913","article-title":"DMD exon 1 truncating point mutations: amelioration of phenotype by alternative translation initiation in exon 6","volume":"30","author":"Gurvich","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2022.10.025_bib32","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/bs.pmbts.2021.01.029","article-title":"Gene editing and modulation for Duchenne muscular dystrophy","volume":"182","author":"Stephenson","year":"2021","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.omtn.2022.10.025_bib33","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1038\/mtna.2014.1","article-title":"The dynamics of compound, transcript, and protein effects after treatment with 2OMePS antisense oligonucleotides in mdx mice","volume":"3","author":"Verhaart","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2022.10.025_bib34","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ajpath.2012.04.006","article-title":"Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino","volume":"181","author":"Wu","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.omtn.2022.10.025_bib35","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1073\/pnas.0406700102","article-title":"Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles","volume":"102","author":"Lu","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2022.10.025_bib36","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/ana.21627","article-title":"Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs","volume":"65","author":"Yokota","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2022.10.025_bib37","first-page":"1202","article-title":"Antisense oligonucleotides for the treatment of cardiomyopathy in Duchenne muscular dystrophy","volume":"11","author":"Nguyen","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.omtn.2022.10.025_bib38","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1093\/nar\/gkt1220","article-title":"Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells","volume":"42","author":"Lehto","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2022.10.025_bib39","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/gt.2009.120","article-title":"Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino","volume":"17","author":"Wu","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtn.2022.10.025_bib40","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1073\/pnas.1613203114","article-title":"Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy","volume":"114","author":"Echigoya","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2022.10.025_bib41","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1038\/mtna.2012.30","article-title":"Pip6-PMO, A new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment","volume":"1","author":"Betts","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2022.10.025_bib42","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/mt.2008.52","article-title":"Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle","volume":"16","author":"Townsend","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2022.10.025_bib43","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/nat.2011.0306","article-title":"Long-term systemic administration of unconjugated morpholino oligomers for therapeutic expression of dystrophin by exon skipping in skeletal muscle: implications for cardiac muscle integrity","volume":"21","author":"Malerba","year":"2011","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2022.10.025_bib44","doi-asserted-by":"crossref","first-page":"e0198897","DOI":"10.1371\/journal.pone.0198897","article-title":"Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-\/-mdx mouse models of Duchenne muscular dystrophy","volume":"13","author":"Blain","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2022.10.025_bib45","series-title":"Muscle Biopsy : A Practical Approach","author":"Dubowitz","year":"2020"}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253122002918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253122002918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:31:01Z","timestamp":1761874261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253122002918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":45,"alternative-id":["S2162253122002918"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2022.10.025","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic PPMO-mediated dystrophin expression in the Dup2 mouse model of Duchenne muscular dystrophy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2022.10.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors.","name":"copyright","label":"Copyright"}]}}